Gilead dodges Supreme Court review—and a $1.2B fine—in CAR-T patent feud with Bristol Myers

After years of courtroom drama and amid a market clash, Bristol Myers Squibb has failed to open a new legal front in its cell therapy war with Gilead Sciences.